Management protocol for abacavir-related hypersensitivity reaction

Annals of Pharmacotherapy

Volumn 34, Issue 2, 2000, Pages 247-249

  Clay, Patrick G ^a,b   Rathbun, R Chris ^c   Slater, Leonard N ^d  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Abacavir; Hypersensitivity

Indexed keywords

ABACAVIR; ANTIHISTAMINIC AGENT; CORTICOSTEROID;

ARTICLE; CLINICAL FEATURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; PATIENT EDUCATION; PRIORITY JOURNAL;

ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; HIV INFECTIONS; HUMANS;

EID: 0033953512     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19107     Document Type: Article

References (14)

1. Kakuda TN, Acosta EP, Fletcher CV. Potential confusion with antiretroviral drugs (letter). Am J Health-Syst Pharm 1998;55:2639-40.
2. Johnson JT, Dunn EB, Wolfe JJ. Two antiretrovirals likely to be confused (letter). Am J Health-Syst Pharm 1998;55:1728-9.
3. Von Bargen J, Moorman A, Holmberg S. How many pills do patients with HIV infection take? (letter). JAMA 1998;280:29.
4. Fauci AS, Bartlett JG, Goosby EP, Smith MD, Chang SW. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep 1999;48:459.
5. McEvoy, GK, ed. American Hospital Formulary Service drug information 1998. Bethesda, MD: American Society of Health System Pharmacists, 1998:560-2.
6. Package insert. Rescriptor (delavirdine mesylate). Kalamazoo, MI: Pharmacia & Upjohn, April 1997.
7. Package insert. Sustiva (efavirenz capsules). Wilmington, IL: DuPont Pharmaceuticals, 1998.
8. Package insert. Ziagen (abacavir sulfate). Research Triangle Park, NC: Glaxo Wellcome, December 1998.
9. 603:Ziagen hypersensitivity reactions. GlaxoWellcome Oncology/HIV Faxback Service. Research Triangle Park, NC: GlaxoWellcome, May 11, 1999.
10. Staszewski S, Katlama C, Harrer T, Massip P, Yeni P, Cutrell A, et al. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. AIDS 1998;12:F197-202.
11. Abacavir for treatment of HIV infection. Am Fam Physician 1999;59: 1329.
12. Foster RH, Faulds D. Abacavir. Drugs 1998;55:729-36.
13. Saag MS, Sonnerberg A, Torres RA, Lancaster D, Gazzard B, Schooley R, et al. Antiretroviral effect and safely of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team. AIDS 1998;12:F203-9.
14. Kessler H, Follansbee S, Sension M, Johnson J, Hetherington S. Safety and efficacy of abacavir in an open-labeled program. In: Program and Abstracts of 36th Annual Meeting of the Infectious Diseases Society of America, Denver, CO: November 12-15, 1998.